Pressmeddelanden från Lytix Biopharma

Bevaka pressreleaser

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Lytix Biopharma

Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab 21 maj 07:05

Lytix Biopharma

Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances 15 maj 10:23

Lytix Biopharma

Lytix Biopharma: Invitation to the Q1 2026 Results Presentation 06 maj 07:05

Lytix Biopharma

New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma 21 apr 16:05

Lytix Biopharma

Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 21 apr 07:05

Lytix Biopharma

Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma 16 apr 23:25

Lytix Biopharma

Lytix Biopharma ASA - Conversion to public limited liability company and name change registered 14 apr 17:12

Lytix Biopharma

Lytix Biopharma AS: Minutes from Annual General Meeting 09 apr 20:57

Lytix Biopharma

Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS 07 apr 07:05

Lytix Biopharma

Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth 25 mar 09:18

Lytix Biopharma

Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 24 mar 07:13

Lytix Biopharma

Lytix Biopharma AS: Annual Report for 2025 18 mar 07:05

Lytix Biopharma

Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 24 feb 12:23

Lytix Biopharma

Lytix Biopharma AS - New share capital registered 17 feb 08:53

Lytix Biopharma

Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)12 feb 07:05

Lytix Biopharma

Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report 05 feb 12:33

Lytix Biopharma

Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report 18 nov 2025 07:00

Lytix Biopharma

Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy 14 nov 2025 07:05

Lytix Biopharma

Lytix Biopharma: Invitation to Q3 2025 Results Presentation 11 nov 2025 07:00

Lytix Biopharma

Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital 10 nov 2025 07:00

Lytix Biopharma

New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide 08 okt 2025 07:05

Lytix Biopharma

Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 01 sep 2025 19:55

Lytix Biopharma

Lytix Biopharma AS: Grant of share options to management and key personnel 28 aug 2025 07:07

Lytix Biopharma

Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization 21 aug 2025 14:08

Lytix Biopharma

Lytix Biopharma: Invitation to Q2 2025 Results Presentation 15 maj 2025 07:05

Lytix Biopharma

Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress 09 maj 2025 07:10

Lytix Biopharma

Lytix Biopharma: Invitation to Q1 2025 Results Presentation 29 apr 2025 14:27

Lytix Biopharma

Lytix Biopharma AS reshuffled its Board after the Ordinary General Meeting 22 apr 2025 21:33

Lytix Biopharma

Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair 10 apr 2025 07:20

Lytix Biopharma

Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 10 apr 2025 07:05

Lytix Biopharma

Lytix Biopharma AS: Annual Report for 2024 13 feb 2025 08:05

Lytix Biopharma

Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 12 feb 2025 08:05

Lytix Biopharma

Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program 07 feb 2025 09:06

Lytix Biopharma

Lytix Biopharma: Invitation to Q4 2024 Results Presentation 22 jan 2025 08:05

Lytix Biopharma

Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference 15 jan 2025 16:01

Lytix Biopharma

Lytix Biopharma AS - New share capital registered 07 jan 2025 19:18

Lytix Biopharma

Lytix Biopharma AS - Cancellation of Subsequent Offering 23 dec 2024 17:26

Lytix Biopharma

Lytix Biopharma AS - New share capital registered 17 dec 2024 08:05

Lytix Biopharma

Lytix Biopharma AS: Key information relating to potential subsequent offering 17 dec 2024 08:05

Lytix Biopharma

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates 17 dec 2024 00:30

Lytix Biopharma

Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed 16 dec 2024 17:09

Lytix Biopharma

Lytix Biopharma – Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement 16 dec 2024 17:04

Lytix Biopharma

Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid 21 nov 2024 15:48

Lytix Biopharma

Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion 19 nov 2024 07:05

Lytix Biopharma

Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization 12 nov 2024 10:33

Lytix Biopharma

Lytix Biopharma: Invitation to Q3 2024 Results Presentation 06 nov 2024 22:23

Lytix Biopharma

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma 05 nov 2024 07:05

Lytix Biopharma

Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals 24 okt 2024 14:19

Lytix Biopharma

Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference 29 aug 2024 08:05

Lytix Biopharma

Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization 23 aug 2024 08:05

Lytix Biopharma

Lytix Biopharma: Invitation to Q2 2024 Results Presentation 14 aug 2024 13:44

Lytix Biopharma

PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy 06 aug 2024 16:51

Lytix Biopharma

Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14 30 maj 2024 07:03

Lytix Biopharma

Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones 22 maj 2024 11:47

Lytix Biopharma

Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024 14 maj 2024 14:29

Lytix Biopharma

Lytix Biopharma – Minutes of Ordinary General Meeting 13 maj 2024 15:16

Lytix Biopharma

Lytix Biopharma AS - New share capital registered 03 maj 2024 16:39

Lytix Biopharma

Correction in the notice of Annual General Meeting in Lytix Biopharma AS 30 apr 2024 07:05

Lytix Biopharma

Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024 30 apr 2024 07:00

Lytix Biopharma

Lytix Biopharma AS: Annual Report for 2023 26 apr 2024 16:06

Lytix Biopharma

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates 26 apr 2024 15:49

Lytix Biopharma

Lytix Biopharma AS – Share issue pursuant to board authorisation 25 apr 2024 17:13

Lytix Biopharma

Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates 25 apr 2024 16:18

Lytix Biopharma

Lytix Biopharma AS – Minutes of extraordinary general meeting and final results of share offering 25 apr 2024 13:48

Lytix Biopharma

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity 24 apr 2024 21:55

Lytix Biopharma

Lytix Biopharma AS – Preliminary results in the share offering 24 apr 2024 07:00

Lytix Biopharma

Lytix Biopharma AS - Last day of the Application Period 09 nov 2023 08:00

Lytix Biopharma

Lytix Biopharma presents third quarter 2023 results 08 nov 2023 12:00

Lytix Biopharma

Lytix Biopharma presenting at major investor conferences in London and Stockholm in November 23 okt 2023 08:02

Lytix Biopharma

Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023 17 okt 2023 08:00

Lytix Biopharma

Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’16 okt 2023 08:52

Lytix Biopharma

Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published.09 okt 2023 15:00

Lytix Biopharma

Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting 31 aug 2023 08:00

Lytix Biopharma

Lytix Biopharma presents first half and second quarter 2023 results 28 aug 2023 13:59

Lytix Biopharma

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial 11 aug 2023 08:00

Lytix Biopharma

Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase 2 data with LTX-315 03 aug 2023 15:02

Lytix Biopharma

Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting 20 jul 2023 09:00

Lytix Biopharma

Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023.